Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC decreased its position in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 37.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,249,069 shares of the company's stock after selling 3,200,679 shares during the period. Annexon accounts for about 3.2% of Bain Capital Life Sciences Investors LLC's investment portfolio, making the stock its 9th biggest position. Bain Capital Life Sciences Investors LLC owned approximately 4.92% of Annexon worth $26,928,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. E Fund Management Co. Ltd. lifted its stake in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after purchasing an additional 4,086 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Annexon by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock worth $1,376,000 after buying an additional 4,806 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Annexon by 4.3% during the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock worth $728,000 after acquiring an additional 5,854 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Annexon by 2.8% during the fourth quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company's stock valued at $1,183,000 after acquiring an additional 6,226 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of Annexon by 17.7% during the fourth quarter. MetLife Investment Management LLC now owns 64,967 shares of the company's stock worth $333,000 after purchasing an additional 9,755 shares in the last quarter.

Annexon Trading Down 1.6 %

Shares of NASDAQ:ANNX traded down $0.03 on Friday, hitting $1.88. 865,808 shares of the company were exchanged, compared to its average volume of 1,820,938. The firm has a market capitalization of $206.25 million, a P/E ratio of -1.79 and a beta of 1.24. Annexon, Inc. has a 1-year low of $1.29 and a 1-year high of $7.85. The stock's 50 day moving average price is $2.17 and its 200 day moving average price is $4.26.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). On average, equities analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.